PLCE1 rs2274223 A>G polymorphism and cancer risk

A meta-analysis

Meenakshi Umar, Rohit Upadhyay, Balraj Mittal

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Phospholipase C epsilon 1 gene (PLCE1) encodes a phospholipase enzyme which regulates various physiological processes (cell growth, differentiation, and apoptosis) and is supposed to play a critical role in carcinogenesis. Recently, a single nucleotide polymorphism (rs2274223 A>G) in PLCE1 was reported as a novel susceptibility locus for esophageal and gastric cancers by genome-wide association studies performed in Chinese population. However, individual association studies replicating this finding showed inconclusive results. Therefore, we performed a meta-analysis of eligible studies to derive precise estimation of the association of PLCE1 rs2274223 A>G polymorphism with cancer risk. We performed pooled analysis of 12 case-control studies including 7,622 cases and 9,555 controls. Odds ratios and 95 % confidence interval were calculated to assess strength of association in overall studies and in subgroup analysis stratified by ethnicity, cancer types, and source of controls. All statistical analyses were performed by MIX 2.0 software. We found that PLCE1 rs2274223 A>G polymorphism was significantly associated with increased risk of cancer in log additive/dominant model and at allele level (GG vs. AA: OR = 1.24, 95 % CI = 1.01-1.53, P = 0.039; AG vs. AA: OR = 1.24, 95 % CI = 1.16-1.32, P < 0.001; AG + GG vs. AA: OR = 1.22, 95 % CI = 1.12-1.34, P < 0.001; and G vs. A allele: OR = 1.15, 95 % CI = 1.05-1.25, P = 0.002). Further, stratified analysis showed elevated risk of only gastric and esophageal tumors. Sub-group analysis based on ethnicity suggests PLCE1 polymorphism conferred significant risk among Asian (Chinese) but not in Caucasian. In conclusion, PLCE1 rs2274223 polymorphism may be used as potential biomarker for cancer susceptibility particularly for esophageal/gastric cancer and for the Chinese population.

Original languageEnglish
Pages (from-to)3537-3544
Number of pages8
JournalTumor Biology
Volume34
Issue number6
DOIs
Publication statusPublished - 1 Dec 2013
Externally publishedYes

Fingerprint

Meta-Analysis
Genes
Neoplasms
Esophageal Neoplasms
Stomach Neoplasms
Alleles
Physiological Phenomena
Phospholipases
Genome-Wide Association Study
Tumor Biomarkers
Population
Single Nucleotide Polymorphism
phospholipase C epsilon
Case-Control Studies
Cell Differentiation
Stomach
Carcinogenesis
Software
Odds Ratio
Confidence Intervals

Keywords

  • Cancer
  • Meta-analysis
  • PLCE1
  • Polymorphism

ASJC Scopus subject areas

  • Cancer Research

Cite this

PLCE1 rs2274223 A>G polymorphism and cancer risk : A meta-analysis. / Umar, Meenakshi; Upadhyay, Rohit; Mittal, Balraj.

In: Tumor Biology, Vol. 34, No. 6, 01.12.2013, p. 3537-3544.

Research output: Contribution to journalArticle

Umar, Meenakshi ; Upadhyay, Rohit ; Mittal, Balraj. / PLCE1 rs2274223 A>G polymorphism and cancer risk : A meta-analysis. In: Tumor Biology. 2013 ; Vol. 34, No. 6. pp. 3537-3544.
@article{9a62947e9c6742538da712ec272ed24f,
title = "PLCE1 rs2274223 A>G polymorphism and cancer risk: A meta-analysis",
abstract = "Phospholipase C epsilon 1 gene (PLCE1) encodes a phospholipase enzyme which regulates various physiological processes (cell growth, differentiation, and apoptosis) and is supposed to play a critical role in carcinogenesis. Recently, a single nucleotide polymorphism (rs2274223 A>G) in PLCE1 was reported as a novel susceptibility locus for esophageal and gastric cancers by genome-wide association studies performed in Chinese population. However, individual association studies replicating this finding showed inconclusive results. Therefore, we performed a meta-analysis of eligible studies to derive precise estimation of the association of PLCE1 rs2274223 A>G polymorphism with cancer risk. We performed pooled analysis of 12 case-control studies including 7,622 cases and 9,555 controls. Odds ratios and 95 {\%} confidence interval were calculated to assess strength of association in overall studies and in subgroup analysis stratified by ethnicity, cancer types, and source of controls. All statistical analyses were performed by MIX 2.0 software. We found that PLCE1 rs2274223 A>G polymorphism was significantly associated with increased risk of cancer in log additive/dominant model and at allele level (GG vs. AA: OR = 1.24, 95 {\%} CI = 1.01-1.53, P = 0.039; AG vs. AA: OR = 1.24, 95 {\%} CI = 1.16-1.32, P < 0.001; AG + GG vs. AA: OR = 1.22, 95 {\%} CI = 1.12-1.34, P < 0.001; and G vs. A allele: OR = 1.15, 95 {\%} CI = 1.05-1.25, P = 0.002). Further, stratified analysis showed elevated risk of only gastric and esophageal tumors. Sub-group analysis based on ethnicity suggests PLCE1 polymorphism conferred significant risk among Asian (Chinese) but not in Caucasian. In conclusion, PLCE1 rs2274223 polymorphism may be used as potential biomarker for cancer susceptibility particularly for esophageal/gastric cancer and for the Chinese population.",
keywords = "Cancer, Meta-analysis, PLCE1, Polymorphism",
author = "Meenakshi Umar and Rohit Upadhyay and Balraj Mittal",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/s13277-013-0932-7",
language = "English",
volume = "34",
pages = "3537--3544",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "6",

}

TY - JOUR

T1 - PLCE1 rs2274223 A>G polymorphism and cancer risk

T2 - A meta-analysis

AU - Umar, Meenakshi

AU - Upadhyay, Rohit

AU - Mittal, Balraj

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Phospholipase C epsilon 1 gene (PLCE1) encodes a phospholipase enzyme which regulates various physiological processes (cell growth, differentiation, and apoptosis) and is supposed to play a critical role in carcinogenesis. Recently, a single nucleotide polymorphism (rs2274223 A>G) in PLCE1 was reported as a novel susceptibility locus for esophageal and gastric cancers by genome-wide association studies performed in Chinese population. However, individual association studies replicating this finding showed inconclusive results. Therefore, we performed a meta-analysis of eligible studies to derive precise estimation of the association of PLCE1 rs2274223 A>G polymorphism with cancer risk. We performed pooled analysis of 12 case-control studies including 7,622 cases and 9,555 controls. Odds ratios and 95 % confidence interval were calculated to assess strength of association in overall studies and in subgroup analysis stratified by ethnicity, cancer types, and source of controls. All statistical analyses were performed by MIX 2.0 software. We found that PLCE1 rs2274223 A>G polymorphism was significantly associated with increased risk of cancer in log additive/dominant model and at allele level (GG vs. AA: OR = 1.24, 95 % CI = 1.01-1.53, P = 0.039; AG vs. AA: OR = 1.24, 95 % CI = 1.16-1.32, P < 0.001; AG + GG vs. AA: OR = 1.22, 95 % CI = 1.12-1.34, P < 0.001; and G vs. A allele: OR = 1.15, 95 % CI = 1.05-1.25, P = 0.002). Further, stratified analysis showed elevated risk of only gastric and esophageal tumors. Sub-group analysis based on ethnicity suggests PLCE1 polymorphism conferred significant risk among Asian (Chinese) but not in Caucasian. In conclusion, PLCE1 rs2274223 polymorphism may be used as potential biomarker for cancer susceptibility particularly for esophageal/gastric cancer and for the Chinese population.

AB - Phospholipase C epsilon 1 gene (PLCE1) encodes a phospholipase enzyme which regulates various physiological processes (cell growth, differentiation, and apoptosis) and is supposed to play a critical role in carcinogenesis. Recently, a single nucleotide polymorphism (rs2274223 A>G) in PLCE1 was reported as a novel susceptibility locus for esophageal and gastric cancers by genome-wide association studies performed in Chinese population. However, individual association studies replicating this finding showed inconclusive results. Therefore, we performed a meta-analysis of eligible studies to derive precise estimation of the association of PLCE1 rs2274223 A>G polymorphism with cancer risk. We performed pooled analysis of 12 case-control studies including 7,622 cases and 9,555 controls. Odds ratios and 95 % confidence interval were calculated to assess strength of association in overall studies and in subgroup analysis stratified by ethnicity, cancer types, and source of controls. All statistical analyses were performed by MIX 2.0 software. We found that PLCE1 rs2274223 A>G polymorphism was significantly associated with increased risk of cancer in log additive/dominant model and at allele level (GG vs. AA: OR = 1.24, 95 % CI = 1.01-1.53, P = 0.039; AG vs. AA: OR = 1.24, 95 % CI = 1.16-1.32, P < 0.001; AG + GG vs. AA: OR = 1.22, 95 % CI = 1.12-1.34, P < 0.001; and G vs. A allele: OR = 1.15, 95 % CI = 1.05-1.25, P = 0.002). Further, stratified analysis showed elevated risk of only gastric and esophageal tumors. Sub-group analysis based on ethnicity suggests PLCE1 polymorphism conferred significant risk among Asian (Chinese) but not in Caucasian. In conclusion, PLCE1 rs2274223 polymorphism may be used as potential biomarker for cancer susceptibility particularly for esophageal/gastric cancer and for the Chinese population.

KW - Cancer

KW - Meta-analysis

KW - PLCE1

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84885669446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885669446&partnerID=8YFLogxK

U2 - 10.1007/s13277-013-0932-7

DO - 10.1007/s13277-013-0932-7

M3 - Article

VL - 34

SP - 3537

EP - 3544

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 6

ER -